| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Avridine is an immunomodulator and interferon-inducing agent. Its primary target is the immune system, where it acts as a potent adjuvant. However, it does not have a specific molecular target like an enzyme or receptor.
|
|---|---|
| ln Vitro |
In vitro, Avridine's activity is characterized by its immunomodulatory effects. As a synthetic adjuvant, its primary in vitro functions are related to its ability to stimulate immune cells and cytokine production.
|
| ln Vivo |
CP-20961 can be employed in animal modeling to create models of arthritis in animals.
In vivo, Avridine is a potent adjuvant that can induce arthritis in most rat strains. The arthritis induced is severe and long-lasting in LEW and DA rats. This makes it a valuable tool for studying the mechanisms of arthritis and for screening anti-arthritic drugs. |
| Enzyme Assay |
As a synthetic adjuvant, Avridine's activity is not measured in typical cell-free enzyme or receptor assays. Its effects are assessed in cell-based or in vivo systems.
|
| Cell Assay |
Avridine's immunomodulatory effects are studied in cell-based assays. These include measuring its ability to stimulate cytokine production or enhance immune responses in various immune cell types.
|
| Animal Protocol |
Animal/Disease Models: Female, Hartley guinea pig, weighing 350 to 400 grams [3].
Doses: 10 mg/kg. Route of Administration: Administer intravenously (iv) (iv)(iv) 24, 48, or 72 hrs (hrs (hours)) after burn injury. Experimental Results: There was no effect on survival after challenge with Pseudomonas aeruginosa 96 hrs (hrs (hours)) after burn injury. In vivo, Avridine is used to induce arthritis in rat strains such as LEW and DA. The severity and duration of arthritis are monitored, and the model is used for studying the pathogenesis of arthritis and for testing potential therapeutic interventions. |
| ADME/Pharmacokinetics |
Pharmacokinetic data for Avridine is not detailed in the available literature. As an adjuvant, its properties are studied in the context of its immune-stimulating effects.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Avridine is not provided. However, its ability to induce arthritis indicates a significant inflammatory effect, which is the basis of its use as a research tool.
|
| References | |
| Additional Infomation |
Avridine is an amino alcohol.
Avridine is a research tool for studying immunology and arthritis. Its ability to induce a severe, long-lasting arthritis in rats makes it a valuable model for understanding the mechanisms of autoimmune arthritis and for evaluating the efficacy of new anti-inflammatory and immunomodulatory drugs. |
| Molecular Formula |
C43H90N2O2
|
|---|---|
| Molecular Weight |
667.1869
|
| Exact Mass |
666.7
|
| CAS # |
35607-20-6
|
| PubChem CID |
37186
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
0.892g/cm3
|
| Boiling Point |
717.6ºC at 760mmHg
|
| Flash Point |
294.3ºC
|
| Index of Refraction |
1.478
|
| LogP |
12.488
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
42
|
| Heavy Atom Count |
47
|
| Complexity |
504
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WXNRAKRZUCLRBP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C43H90N2O2/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-36-44(38-35-39-45(40-42-46)41-43-47)37-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h46-47H,3-43H2,1-2H3
|
| Chemical Name |
2-[3-(dioctadecylamino)propyl-(2-hydroxyethyl)amino]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4988 mL | 7.4941 mL | 14.9882 mL | |
| 5 mM | 0.2998 mL | 1.4988 mL | 2.9976 mL | |
| 10 mM | 0.1499 mL | 0.7494 mL | 1.4988 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
